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Abstract
We have recently developed a candidate HIV-1 vaccine model based on HIV-1 Pr55gag Virus-Like
Particles (HIV-VLPs), produced in a baculovirus expression system and presenting a gp120
molecule from an Ugandan HIV-1 isolate of the clade A (HIV-VLPAs).
The HIV-VLPAs induce in Balb/c mice systemic and mucosal neutralizing Antibodies as well as
cytotoxic T lymphocytes, by intra-peritoneal as well as intra-nasal administration. Moreover, we
have recently shown that the baculovirus-expressed HIV-VLPs induce maturation and activation of
monocyte-derived dendritic cells (MDDCs) which, in turn, produce Th1- and Th2-specific
cytokines and stimulate in vitro a primary and secondary response in autologous CD4+ T cells.
In the present manuscript, the effects of the baculovirus-expressed HIV-VLPAs on the genomic
transcriptional profile of MDDCs obtained from normal healthy donors have been evaluated. The
HIV-VLPA stimulation, compared to both PBS and LPS treatment, modulate the expression of genes
involved in the morphological and functional changes characterizing the MDDCs activation and
maturation.
The results of gene profiling analysis here presented are highly informative on the global pattern of
gene expression alteration underlying the activation of MDDCs by HIV-VLPAs at the early stages
of the immune response and may be extremely helpful for the identification of exclusive activation
markers.
Introduction
Virus-like particles (VLPs) represent a peculiar form of
subunit vaccine based on viral capsid and envelope pro-
teins which show the ability to self-assemble into highly
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organized particulate structures [1,2]. VLPs closely resem-
ble immature virus particles but are both replication and
infection incompetent, lacking regulatory proteins as well
as infectious genetic material. VLPs can be employed to
deliver additional antigenic structures, such as whole pro-
teins or specific individual epitopes and have been shown
to generally induce more effective humoral and cellular
immune response than their soluble counterparts [3].
Considering all these properties, VLPs represent a highly
attractive vaccine approach and have been produced from
a broad spectrum of enveloped and non-enveloped
viruses, regardless of whether the particle structure is
based on single or multiple capsid proteins [4].
The VLPs developed in our laboratory are based on the
Human Immunodeficiency Virus type 1 Pr55gag precur-
sor protein (HIV-VLPs) and present an entire gp120 mol-
ecule, anchored through the trans-membrane (TM)
portion of the Epstein-Barr virus (EBV) gp220/350 [5].
The gp120 glycoprotein selected for these HIV-VLPs
derives from an Ugandan HIV-1 isolate of the A clade
[6,7], which represents the second most prevalent HIV-1
subtype worldwide (approx. 25%) and is predominant in
many developing countries (HIV-VLPAs).
The HIV-VLPAs show a strong in vivo immunogenicity in
Balb/c mice, even in absence of adjuvants, and HIV-1-spe-
cific T cell response (CD4+ and CD8+) as well as cross-
clade neutralizing antibodies have been detected in
immunized animals [8]. Moreover, the intra-peritoneal
and the intra-nasal administrations of HIV-VLPAs induce
in mice an antibody response at systemic as well as local
(vaginal and intestinal) level [9].
Most of the VLPs developed have been shown to be highly
effective at stimulating CD4 proliferative responses and
cytotoxic T lymphocyte (CTL) responses in addition to B-
cell-mediated humoral immunity [4]. These properties
suggest the ability to promote the activation of antigen-
presenting cells (APCs) and a cross-presentation of pep-
tides in association to both MHC class I and -II molecules
[10,11].
We have recently shown that baculovirus-expressed HIV-
VLPAs are able to induce maturation of DCs, resulting in
expression of surface maturation markers as well as
increased production of Th1 polarizing cytokines, and
this effect is partially mediated by the intra-cellular TLRs 3
and 8. The HIV-VLP-activated DCs induce a primary and
secondary response in autologous CD4+ T cells, in an in
vitro immunization assay. Finally, the uptake of HIV-VLPs
by DCs appears to be mainly mediated by an endocytosis-
mediated pathway (Buonaguro L, et al., submitted).
Dendritic cells (DCs) are professional antigen-presenting
cells (APC) able to initiate immune responses [12,13].
Immature DCs are located in peripheral tissues to contin-
uously monitor the environment through the uptake of
particulate and soluble products. Antigen-loaded DCs
acquire a mature phenotype, associated with reduced
endocytic and phagocytic capacities, and enhanced pro-
duction of inflammatory cytokines and chemokines [14-
17]. The mature DCs, then, migrate toward the lymphoid
organs where they interact with, and activate, naïve T cells
[18].
The analysis of the transcription profile, defined as tran-
scriptome, is highly informative of the molecular basis
underlying the morphological, phenotypical and func-
tional changes of specific immune cell populations
induced by specific stimuli. In particular, gene-expression
profiles of human Th1 and Th2 cells have allowed the
identification of genetic patterns involved in the differen-
tial T helper cell polarization [19]. Similarly, selected
genes differentially regulated during the transition from a
B cell to plasma cell have been identified, which are
involved in the Ab secretion, homeostasis, migration, and
differentiation [20].
More recently, the expression pattern of specific sets of
genes upon DC differentiation and maturation has been
reported, showing a great plasticity of the DC transcrip-
tional programs, activated in response to CD40L, LPS and
cocktail of inflammatory cytokines and prostaglandin
(PG) E(2) (CyC) [21,22]. Furthermore, a time-specific
kinetic of response has been observed in MDDC activated
with pathogen components, showing a rapid upregula-
tion of genes associated with the innate arm of the
immune response, followed by induction of adaptive
immune response genes [23-25].
In this study, we have analyzed the changes in the gene
expression of immature human monocyte-derived DC
(MDDC) activated with the baculovirus-expressed HIV-
VLPs developed in our laboratory. The transcriptional pat-
tern has been evaluated after 4 and 8 hours of induction
with HIV-VLPs and the results show the sustained
increased expression of specific genes involved in the
morphological and functional changes characterizing the
MDDCs activation and maturation.
Materials and methods
Cell culture medium
DC culture medium consisted of RPMI 1640 medium
(Life Technologies, Carlsbad, Calif.) supplemented with 2
mM L-glutamine (Sigma), 1% nonessential amino acids
(Life Technologies), 1% sodium pyruvate (Life Technolo-
gies), 50 µM 2-mercaptoethanol (Sigma), 50 µg of gen-Journal of Translational Medicine 2005, 3:45 http://www.translational-medicine.com/content/3/1/45
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tamicin (Life Technologies) per ml, and 10% fetal calf
serum (Life Technologies).
DC preparation and treatment
All human specimens were obtained under informed con-
sent, as approved by the University of Maryland Baltimore
Institutional Review Board. Monocyte-derived DCs were
generated as described previously (17), with minor mod-
ifications. Briefly, human peripheral blood mononuclear
cells were isolated, from three independent normal
healthy donors, by Ficoll-Hypaque density gradient cen-
trifugation and were enriched for CD14+ monocytes by
negative selection with a cocktail of monoclonal antibod-
ies from StemCell Technologies (Vancouver, British
Columbia, Canada), according to the instructions of the
manufacturer. Typically, greater than 80% of the cells
were CD14+ after enrichment (data not shown). The iso-
lated monocytes were allowed to adhere to plastic by plat-
ing 106 cells per/ml in RPMI 1640 medium for 2 h.
Adherent monocytes were washed with RPMI 1640
medium and were then cultured for 6 days at 106 cells per/
ml in DC culture medium supplemented with 50 ng of
recombinant GM-CSF (rGM-CSF, R&D Systems, Minne-
apolis, Minn.) per ml and 1,000 U of recombinant IL-4
(rIL-4; R&D Systems, Minneapolis, Minn.) per ml.
After 6 days in culture, MDDCs were pulsed with either 5
µg/ml of HIV-VLPs or 1 µg/ml of LPS for 4 and 8 hours,
for gene microarray analysis, and for 16 hours for matura-
tion and activation phenotype analysis.
Analysis of DC phenotype
DCs were incubated for 30 min at 4°C with murine mon-
oclonal antibodies specific for CD80, CD83, CD86, and
HLA-DR (BD Pharmingen, San Diego, CA), washed and
then fixed with 2% paraformaldehyde for analysis with a
FACScalibur flow cytometer (BD Pharmingen). Data anal-
ysis was carried out with FlowJo software (Tree Star Inc.,
San Carlos, CA). The fraction of MDDCs that responded
by upregulation of activation markers on the cell surface
was calculated by overlaying the histograms of treated and
untreated MDDCs and Overton subtraction of the curves.
RNA preparation and microarray hybridization
DCs were harvested, washed twice in PBS and lysed in 350
ul RLT buffer with fresh addition of 2-Mercaptoethanol
per each well of the 6-well plate. Total RNA was isolated
using RNeasy minikits (Qiagen), according to the manu-
facturer's protocol, and RNA quality and quantity was esti-
mated by Agilent Bioanlayzer (Agilent Technologies, Palo
Alto, CA) and NonoDrop. Amplified antisense RNA
(aRNA) was obtained from total RNA (0.5–3 µg) via two
round of in vitro transcription, according the protocol
previously described by us [26]. 6 ug of amplified test
samples aRNA were labeled with Cy5 (Amersham) while
the same amount of reference sample (pooled normal
Maturation of DCs by baculovirus-expressed HIV-VLPs Figure 1
Maturation of DCs by baculovirus-expressed HIV-VLPs. Immature MDDCs were incubated in the presence of the indi-
cated stimulus for 16 hours. The expression of CD80, CD83, CD86 and HLA-DR was analyzed on fixed cells by FACScalibur 
flow cytometer and data analysis was carried out with FlowJo software. The results of a representative experiment are shown; 
the shadowed curve represents the untreated cells.
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donor PBMCs) was labeled with Cy3. Test-reference sam-
ple pairs were mixed and co-hybridized to 17K cDNA
microarrays [27].
Microarrays and statistical analyses
Hybridized arrays were scanned at 10-µm resolution on a
GenePix 4000 scanner (Axon Instruments) at variable
PMT voltage to obtain maximal signal intensities with less
than 1% probe saturation. Resulting jpeg and data files
were deposited at microarray data base (mAdb) http://nci
array.nci.nih.gov and retrieved after median centered, fil-
tering of intensity (>300) and spot elimination (bad and
no signal). Data were further analyzed using Cluster and
TreeView software [27] and Partek Pro software (Partek).
Subsequent low-stringency filtering (80% gene presence
across all experiments and at least one experiment with
ratio fold change >3), 3,119 genes were selected for fur-
ther analysis. Hierarchical cluster analysis was conducted
on these genes according to Eisen et al. [28]; differential
expressed genes were visualized by Treeview and dis-
played according to the central method [29].
Results
Baculovirus-HIV-VLP induces a maturation phenotype of 
DCs
Immature MDDCs were obtained from three independent
donors and, after 6 days of culture in IL-4- and GM-CSF-
enrichment medium, were incubated with 5 µg/ml of bac-
ulovirus-expressed HIV-VLPs or 1µg/ml of LPS. In parallel,
control MDDCs were loaded with PBS. After a 16 hr-
induction, the expression of surface maturation/activa-
tion markers, such as CD80, CD83, CD86 and HLA-DR,
was examined. The expression of all the four markers was
upregulated by treatment with HIV-VLPs, compared to
PBS (Fig. 1). The level of cytokines involved in the Th1/
Th2 polarization was assessed in the supernatant of
MDDCs loaded with HIV-VLPs or LPS. In particular, the
TNF-α, IL-12 p70, IL-10 were produced at higher levels in
HIV-VLP-loaded MDDCs compared to LPS-loaded
MDDCs (data not shown).
These results indicate that baculovirus HIV-VLPs induce a
specific MDDC maturation pathway, distinct from the
one induced by the LPS.
Pattern of MDDCs response to HIV-VLPs
Gene expression profiles were generated from treated and
control MDDC harvested 4 and 8 hrs after stimulation.
These time points were selected to evaluate a possible
biphasic response, as described for LPS-induced DCs and
mononuclear phagocytes (MPs) [23,25]. Amplified anti-
sense RNA (aRNA) was obtained from total RNA extracts
[26] and hybridized to a custom-made 17,000 (17K)-
clone cDNA microarray chip enriched with genes relevant
to immune function. Stringent filtering were further
applied to eliminate genes with missing value in >20% of
all the experiments and >3 fold change in at least one
experiment. The remaining 3,119 genes were thus used for
statistic analysis.
Unsupervised cluster analysis obtained on MDDCs stimu-
lated for 4 and 8 hr with HIV-VLPs or LPS shows the seg-
regation of the untreated (PBS) and the treated (HIV-VLPs
or LPS) MDDCs in two independent clusters. However,
within the treated MDDCs cluster, the samples subclus-
tered according to the treatment (HIV-VLPs vs LPS), with
the exception of a single HIV-VLP-treated sample which
formed an independent cluster closer to the LPS-treated
sample, indicating the induction of two distinct transcrip-
Unsupervised hierarchical clustering of all filtered data Figure 2
Unsupervised hierarchical clustering of all filtered 
data. The clusterogram represents 3,119 genes obtained by 
Eisen hierarchical clustering of the complete 17K dataset fil-
tered for genes that are expressed in a minimum of 80% of 
the samples 4 and 8 h after HIV-VLPs or LPS stimulation. The 
PBS treatments was evaluated after 8 h of stimulation. The 
clustering is defined by the dendrogram and each treatment/
time point is represented by a single branch.
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tion machinery. Furthermore, while the HIV-VLP-treated
MDDCs clustered according to the donor, the LPS-treated
MDDCs clustered preferentially according to the treat-
ment duration (4 or 8 hr) of stimulation (Fig. 2). This
would suggest an individual donor susceptibility to HIV-
VLP-treatment and a possible delayed transcription or sec-
ondary response to LPS treatment.
Gene expression changes induced in MDDCs by HIV-VLP 
treatment
The differential gene expression in HIV-VLP-treated
MDDCs, compared to either LPS- or PBS-treated MDDCs,
was considered statistically significant only when sup-
ported by a p < 0.005.
Treatment-induced changes in gene profiling were ana-
lyzed using student t test, based on simple two-treatment
comparison or one versus a combined two-treatment
comparison. Considering only genes showing at least a 2-
fold modulation (increase or reduction) in the transcrip-
tional levels, it has been possible to identify unique and
common genes in the profile induced by the different
treatments. In particular, the HIV-VLP treatment, induced
the upregulation of 140 and 72 genes as well as the down-
regulation of 108 and 46 genes, compared to PBS and LPS
respectively. A sub-set of upregulated and downregulated
genes are specific to the HIV-VLP treatment (Fig. 3), indi-
cating that, besides transcriptional patterns shared with
the LPS treatment, HIV-VLPs induce a specific reprogram-
ming of the MDDCs transcriptional profile.
Visualization of the gene expression among different
treatments revealed a transcriptional profile pattern in
HIV-VLP-induced MDDCs distinct from either PBS or LPS
(4 hr and 8 hr) induction (Fig. 4A). Furthermore, cluster-
ing analysis performed based on 217 genes selectively
expressed (p < 0.005) in HIV-VLP induced MDDCs, com-
pared to LPS treatment, confirmed a distinct transcrip-
tional profiles signature according to the treatment,
regardless of the length of stimulation (Fig. 4B).
Pattern of gene expression in human monocyte-derived DCs Figure 3
Pattern of gene expression in human monocyte-derived DCs. Regulated genes by HIV-VLPs or LPS treatment in 
MDDCs, showing at least a 2-fold modulation (up or downregulation), have been evaluated. Each circle represents the whole 
set of genes identified in the indicated comparisons, based on the 2-fold modulation parameter. Numbers in overlapping 
regions represent common regulated genes. Numbers in non-overlapping regions represent unique regulated genes. Circles 
are drawn in arbitrary scale.
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Pathways modulation in MDDCs in response to HIV-VLPs
Gene expression changes in response to stimuli are gener-
ally pathways directed. In order to analyse pathways mod-
ulated in HIV-VLPs induced MDDCs, we dissected genes
according to cluster nodes derived on the basis of expres-
sion similarity. Supervised cluster analysis based on the
3,119 genes were further analyzed according to pattern
recognition. Genes uniquely upregulated in MDDCs by
HIV-VLPs only or by HIV-VLPs and LPS (either at 4 h or 8
h post-induction) are indicated in Fig. 5A and 5B respec-
tively. Similarly, nodes were identified including genes
down-regulated by HIV-VLPs only or by HIV-VLPs and
LPS at 4 h post-induction (Fig. 5C top and bottom, respec-
tively). Most of the genes present in these nodes are
strictly associated to the functional and morphological
changes characterizing the MDDCs maturation and acti-
vation process.
In this regard, the MDDCs transcriptional profile was ana-
lyzed on the basis of the cellular pathways modulated by
the HIV-VLP-treatment, compared to either PBS or LPS
treatment. In respect to the main focus of this study, only
the pathways involved in the MDDCs-activation by HIV-
VLPs have been evaluated in more detail. These can be
divided into main super-families concerning the cell rep-
lication/death, the transcriptional control, the phagocyto-
sis and pathogen recognition, the immunological
function of dendritic cells, the migration and the control
of the inflammatory responses (Table I).
Supervised hierarchical clustering of genes differentially expressed in HIV-VLP-treated MDDCs Figure 4
Supervised hierarchical clustering of genes differentially expressed in HIV-VLP-treated MDDCs. The clustero-
grams represent an Eisen hierarchical clustering of the 281 genes differentially expressed (p < 0.005) in HIV-VLPs-treated 
MDDCs, compared to PBS treatment (A), and of 217 genes differentially expressed (p < 0.005) in HIV-VLPs-treated MDDCs, 
compared to LPS treatment (B). The clustering is defined by the dendrogram on the top and on the side of the clusterogram.
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The MDDCs differentiation process induced by HIV-VLPs,
in fact, results in the reduced transcriptional levels of
genes associated with phagocytosis and pathogen recogni-
tion. In parallel, an activation of genes associated with
antigen presentation functions is observed. A set of
cytoskeletal genes that may potentially mediate shape
change and migratory behavior of activated DCs is also
observed. The increase in the expression of immune
cytokines, chemokines, and receptors contribute to the
recruitment of monocytes, DCs, and macrophages to the
site of infection. Moreover, they modulate both innate
and adaptive immune response, including the polariza-
tion of Th cells, and the down-regulation of the inflamma-
tory response, which may significantly interfere with the
immune response. The induction of signaling genes and
transcription factors may be involved in preparing the DC
to be receptive to regulatory signals in the lymphatics and
lymph nodes.
Finally, genes involved in the cell replication and apopto-
sis are modulated in their transcriptional levels, in agree-
ment with the observation that mature DC undergo
growth arrest, terminal differentiation and die by apopto-
sis 8–9 days after activation in vivo.
It is not unexpected that many pathways share same genes
with intra-cellular functions involved in several biological
outcomes. The majority (60%) of the pathways specifi-
cally modulated in the MDDCs by the HIV-VLPs treat-
ment result from the comparison with the PBS treatment;
the remaining 40%, instead, derives from the comparison
with both PBS and LPS treatments.
Supervised hierarchical clustering of genes upregulated by HIV-VLPs in MDDCs Figure 5
Supervised hierarchical clustering of genes upregulated by HIV-VLPs in MDDCs. 3,119 genes included in this analy-
sis were filtered upon the criteria of showing less than 20% missing data and a minimum of 3-fold modulation in expression. 
The expanded section shows nodes including genes upregulated by HIV-VLPs. Individual genes are indicated on the right.
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Table 1: Pathways involved in the HIV-VLPs-activated MDDCs. The pathways are derived from the BioCarta through the Cancer Genome Anatomy Project at http://
cgap.nci.nih.gov/Pathways/BioCarta_Pathways. Genes with at least a 2-fold modulation (up or downregulation) have been taken into consideration. Upregulated genes in bold 
and underline; Downregulated genes in plain text.
Pathways HIV-VLP vs PBS HIV-VLP vs LPS Pathways HIV-VLP vs PBS HIV-VLP vs LPS Pathways HIV-VLP vs PBS HIV-VLP vs LPS
Cell cycle, death Transcription Immunology/Signaling
Cadmium induces DNA 
synthesis and proliferation in 
macrophages
NFKB1
MAPK1
TNF Acetylation and Deacetylation 
of RelA in The Nucleus
NFKB1
FADD
NFKBIA
TNF
FADD
AKT Signaling Pathway FOXO3A
NFKB1
CASP9
YWHAH
Caspase Cascade in Apoptosis BIRC3
CASP7
CASP2
CASP9
PARP1
Activation of PKC through G 
protein coupled receptor
GNAQ
NFKB1
B Lymphocyte Cell Surface 
Molecules
CD40
FCGR2A
ICAM1
LTBR
ITGAL
PTPRC
NFKBIA
Free Radical Induced Apoptosis GSR
IL8
NFKB1
Chaperones modulate 
interferon Signaling Pathway
DNAJA3
IFNG
NFKB1
IFNG
LIN7A
NFKBIA
RB1
TNF
CD40L Signaling Pathway CD40
DUSP1
TNFAIP3
TRAF6
IKBKB
DUSP1
MAP3K1
NFKBIA
TNFAIP3
Induction of apoptosis through 
DR3 and DR4/5 Death 
Receptors
BID
CASP10
CASP7
TRAF2
CASP9
FADD
Double Stranded RNA 
Induced Gene Expression
NFKB1 CTL mediated immune 
response against target cells
ICAM1
B2M
LTBR
ITGAL
Neuropeptides VIP and PACAP 
inhibit the apoptosis of activated 
T cells
GNAQ
NFKB1
PRKAR1B
CAMK1
Human Cytomegalovirus and 
Map Kinase Pathways
MAP2K3
NFKB1
MAP2K6
MAPK1
fMLP induced chemokine 
gene expression in HMC-1 
cells
FPR1
MAP2K2
NFKB1
CAMK1
MAP2K6
MAPK1
Regulation of BAD 
phosphorylation
BCL2L1
IGF1R
PRKAR1B
MAPK1
RPS6KA1
YWHAH
NFkB activation by 
Nontypeable Hemophilus 
influenzae
DUSP1
EP300
MAP2K3
NFKB1
NR3C1
SMAD4
MAP2K6
SMAD3
TGFBR2
DUSP1
IL8
NFKBIA
SMAD4
TNF
IKBKB
MAP2K6
SMAD3
Monocyte and its Surface 
Molecules
ICAM1
ICAM2
CD44
LTBR
SELE
CD83
HLA-DOA
ITGAL
PECAM1
Role of Mitochondria in 
Apoptotic Signaling
BCL2L1
BID
BIRC3
CASP7
ENDOG
CASP9
PDCD8
NF-kB Signaling Pathway IRAK1
NFKB1
TNFAIP3
TRAF6
FADD
IL1A
MAP3K1
NFKBIA
TNF
TNFAIP3
FADD
T Cytotoxic Cell Surface 
Molecules
CD8A
ICAM1
LTBR
CD2 ITGAL
PTPRC
SODD/TNFR1 Signaling Pathway BIRC3
TRAF2
FADD
Signal transduction through 
IL1R
IL1B
MAP2K3
NFKB1
TRAF6
IL1RAP
MAP2K6
IL1A
MAP3K1
NFKBIA
TNF
IL1RAP
MAP2K6
T Helper Cell Surface 
Molecules
ICAM1
LTBR
CD2
CD4
ITGAL
PTPRC
Stress Induction of HSP 
Regulation
CASP9
MAPKAPK3
IL1A
TNF
CASP9
CYC1
TNFR1 Signaling Pathway PAK2
TRAF2
CASP2
FADD
PARP1
The 4-1BB-dependent 
immune response
IFNG
NFKB1
TNFSF9
TRAF2J
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TNF/Stress Related Signaling MAP2K3
NFKB1
TANK
TRAF2
CASP2
MAP2K6
TNFR2 Signaling Pathway DUSP1
NFKB1
TANK
TNFAIP3
TRAF2
DUSP1
MAP3K1
NFKBIA
TANK
TNFAIP3
TNFRSF1B
Toll-Like Receptor Pathway IRAK1
MAP2K3
MAP3K7IP2
NFKB1
TRAF6
MAP2K
Pathways HIV-VLP vs PBS HIV-VLP vs LPS Pathways HIV-VLP vs PBS HIV-VLP vs LPS
Cytokine Network Phagocytosis
Cells and Molecules involved in 
local acute inflammatory 
response
ICAM1
IL8
LTBR
CERKL
ITGAL
Instracellular protein 
transport
APG9L1
RERE
RNF4
Cytokine Network IFNG
IL18
IL8
Cytoskeleton
Cytokines and Inflammatory 
Response
CSF1
CSF2
IFNG
IL7
IL8
IL15
IL15RA
IL23
PTGS2
CD4
Cellular motiliyshape ARHGEF2
ARPC2
C14orf43
FLJ39378
MARCKS
PDE4B
PDE5A
PLEK
PPP1R15A
PPP1R15B
SLC11A2
SLC1A3
SLC20A1
SLC43A3
IL 17 Signaling Pathway CD8A
IL8
CD58
CD2
CD4
Th1/Th2 Differentiation IL18
IL18R
Table 1: Pathways involved in the HIV-VLPs-activated MDDCs. The pathways are derived from the BioCarta through the Cancer Genome Anatomy Project at http://
cgap.nci.nih.gov/Pathways/BioCarta_Pathways. Genes with at least a 2-fold modulation (up or downregulation) have been taken into consideration. Upregulated genes in bold 
and underline; Downregulated genes in plain text. (Continued)Journal of Translational Medicine 2005, 3:45 http://www.translational-medicine.com/content/3/1/45
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Functional implementation of activated genes in MDDCs 
in response to HIV-VLPs
The effects of the HIV-VLP treatment on MDDCs, com-
pared to the PBS and LPS treatments, has been analyzed
also considering the individual genes showing increased
transcriptional levels. The presumed biological implica-
tion of selected genes involved in the specific functions of
Dendritic Cells as professional APCs, has been evaluated
in more detail according to their function (Table II).
STAT2 is activated upon the binding of type-I IFN, the
major component of the innate immune system, to its
receptor and participates to the formation of interferon-
stimulated gene factor 3 (ISGF3) complex, composed of
STAT1, STAT2, and IFN regulatory factor 9, which pro-
motes serial synthesis of selected proteins that inhibit
viral replication [30,31].
Macrophage and Granulocyte-Macrophage Colony Stim-
ulating Factor, CSF1 and CSF2, represent the main factors
involved in proliferation and differentiation of myeloid
lineage progenitor cells [32-35]. They may contribute to
an increased production and recruitment of monocytes,
DCs, and macrophages to the site of infection.
Formyl Peptide Receptor (FPR) is responsible for the DC
chemoattraction to the Gram-negative bacteria Formyl
peptide N-formyl-Met-Leu-Phe (fMLP) [35] and to addi-
tional pathogen-derived peptides, including HIV [36,37].
E-Selectin (SELE) and Chemokine (C-C motif) receptor 7
(CCR7) are selectively expressed on mature DCs, follow-
ing encounter with pathogens. They favor the interaction
with the endothelial cells as well as the migration from
peripheral tissues to the T cell areas of secondary lym-
phoid organs, where they produce regulatory cytokines
Table 2: Functional categories of genes differentially upregulated in HIV-VLPs-induced MDDCs. (+) 1.5-fold upregulation; (++) 2–5-fold 
upregulation; (+++) >5-fold upregulation.
Pathway HIV-VLP vs PBS HIV-VLP vs LPS Pathway HIV-VLP vs PBS HIV-VLP vs LPS
Cell cycle, death Chemokine/Immunology
TNF ++ + Innate response
BIRC3 ++ IL8 +++ ++
CASP7 + CXCL1 ++ ++
BID ++ IL1a ++ ++
PAK2 ++ IL1b ++
TRAF2 ++ IL6 ++
BCL2L1 + CCL4 ++
IGF1R ++ IFNG +
TNFAIP3 ++ PTGER4
TANK ++ Adaptive response
PSEN1 + EBI2 ++
TNFRSF1B +++ + ICAM1 ++
Transcription B2M +
NFKB1 + Receptors
NFKBIA ++ IL15RA ++
IRAK1 + IL18R1 ++
MAP3K1 + IL23A ++
JUNB + IL2RB ++
Signaling FCGR2A ++
MAP2K7IP2 + IL7R ++
DUSP1 ++ + CD83 ++
MAP2K3 + Growth Factors
PAK2 ++ CSF1 ++
RB1 + CSF2 +
FOXO3A + Migration and 
Homeostasis
FYN + CCR7 +
GNAQ + FPR1 ++
MEF2A + SELE ++
RAPGEF2 + CD44 ++
LTBR +
T-cell activation/
polarization
CD40 ++
TNFSF9 +
IL18 +Journal of Translational Medicine 2005, 3:45 http://www.translational-medicine.com/content/3/1/45
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and prime naïve T lymphocytes [38,39]. Lymphotoxin-
beta receptor (LTBR) plays a central role in the DC home-
ostasis in lymphoid tissues (spleen and LN), promoting
and sustaining local DC replication [40]. Furthermore, a
set of cytokine receptors that share a common γ chain (IL-
2R, IL-7R, IL-15R, and IL-4R) were also induced and their
expression may allow DCs to respond to lymphocyte-
derived interleukins within the lymph node.
Beta-2-microglobulin (B2M) is one of the components of
the multimolecular peptide-loading MHC class-I complex
within the endoplasmic reticulum (ER) of DCs [41], rep-
resenting the essential process for antigen presentation to
cytotoxic T lymphocytes.
CD40 and TNFSF9 may act as co-stimulatory molecules
which, interacting with the corresponding T cell expressed
ligands, have been shown to play a relevant role in the
activation of T cells. In particular, the CD40:CD40L inter-
action activates the CD4+ cells to promote the sensitiza-
tion of CD8+ cells as well as to induce memory CD8+ T
cell proliferation [42,43]. ICAM-1 is required on the sur-
face of exosomes produced by mature DCs to prime naïve
T cells and trigger effector T-cell response [44].
Supervised hierarchical clustering of genes upregulated by HIV-VLPs and LPS in MDDCs Figure 6
Supervised hierarchical clustering of genes upregulated by HIV-VLPs and LPS in MDDCs. 3,119 genes included in 
this analysis were filtered upon the criteria of showing less than 20% missing data and a minimum of 3-fold modulation in 
expression. The expanded section shows nodes including genes upregulated by HIV-VLPs and LPS-4 h (top) or by HIV-VLPs 
and LPS (bottom). Individual genes are indicated on the right.
PBS (CTR)
LPS 4h
VLP
LPS 8h
Tumor Necrosis Facto 2
TNF – Tumor necrosis Factor
CD79B – CD79B
F3 – Coagulation factor III
CCRL2 – Chemokine receptor 2
PALM2-AKAP2 – Paralemmin 2
IL23A – Interleukin 23a
ARPC2 – Actin related protein 2
BCL2A1 – Bcl-2 related protein
BCL2A1 – BCL2-related protein A1
NFKBIZ – Nuclear factor
RASGRP1- RAS guanyl releasing protein 1
WTAP – Wilms tumor 1 associate protein
ARHGAP4 – Rho GTPase activating protein 4
CSF1 – colony stimulating factor 1 (macrophage)
EHD1 – EH-domain containing 1
EHD1 - EH-domain contaning 1
TNIP2 – TNFAIP3 interacting protein 2
NINJ1 – Ninjurin 1
CCL5 – Chemokine ligand 5
CSF1 – Colony stimulating factor 1 (macrophage)
HSGT1 – Suppressor of S. Cerevisiae
ASCL1 – Acyl-CoA synthetase long-chain family member 1
PLEK – Pleckstrin
KLRC3 – Killer cell lectin-like receptor subfamily C, member 2
PDE5A – Phosphodiesterase 5A
SDC4 – Syndecan-4
ITGAV – integrin, alpha V
ICAM1 – CD54
ICAM1 – CD54
DUSP5 – dual specificity phosphatase 5
Putative lymphocyte G0/G1 switch gene
CCL3 – LD78 beta
CCL3 – Chemokine ligand 3
CCL2 – MCP-1
CCL4 – MIP-1 beta
CCL20 – Chemokine ligand 20
TNFAIP3 – Tumor necrosis factor, alpha-induced protein 3
SOD2 – Superoxidase dismutase 2
SOD2 – Superoxidase dismutase 2
CREM – cAMP responsive element modulator
UNG – uracil DNA-glycosylase
CD44 – Pgp-1 extracellular matrix receptor
SGPP2 – Sphingosine-1-phosphatase
TNFAIP3 – Tumor necrosis factor, alpha-induced protein 3
ITGA6 – integrin alpha 6
DEAF1 – Deformed epidermal autoregulatory factor 1
BIRC3 – Baculovirus IAP repeat-containing 3
SEMA5A – Sema domain, seven thromspondin repeats
PTPLB – Protein tyrosine phosphatase-like
IBRDC2 – IBR domain containing 2
KYNU – Kynureninase
KYNU - KynureninaseJournal of Translational Medicine 2005, 3:45 http://www.translational-medicine.com/content/3/1/45
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IL-18 has been shown to have a Th1/Th2 polarization
effect. In particular, in the presence of IL-12, it enhances
the IL-12-driven Th1 immune response; in the absence of
IL-12, instead, IL-18 can stimulate Th2 cytokine produc-
tion as well as allergic inflammation [45,46].
Collectively, these changes of gene expression in response
to HIV-VLPs reflect a significant cellular and immunolog-
ical reprogramming of the DC.
Conclusion
The results here described confirm that baculovirus-pro-
duced HIV-VLPs induce a maturation pattern in MDDCs
consistent with the one triggered by known activators,
such us LPS, TNFα or cytokine cocktails. The genomic
transcriptional profile induced by HIV-VLPs in MDDCs
shows the activation of unique genes and cellular path-
ways compared to both PBS and LPS induction, reflecting
a distinctive cellular and immunological reprogramming.
An unsupervised Eisen's clustering analysis confirm the
specificity of the observation, given that the MDDCs sam-
ples derived from the HIV-VLP treatment cluster together.
The only sample treated with HIV-VLPs which forms a dif-
ferent cluster on the basis of the 3,119 filtered genes,
aggregates to the HIV-VLP samples when the differentially
expressed genes are considered. This confirms that the pat-
tern of genes specifically modulated by the HIV-VLP treat-
ment is consistent all across the analyzed samples.
Moreover, the genes involved in the transcriptional profile
cluster according preferentially to the donor more than to
the length of stimulation (4 or 8 hr), indicating that the
Supervised hierarchical clustering of genes downregulated by HIV-VLPs and LPS in MDDCs Figure 7
Supervised hierarchical clustering of genes downregulated by HIV-VLPs and LPS in MDDCs. 3,119 genes included 
in this analysis were filtered upon the criteria of showing less than 20% missing data and a minimum of 3-fold modulation in 
expression. The expanded section shows nodes including genes downregulated by HIV-VLPs only or by HIV-VLPs and LPS-4 h 
are shown (top and bottom, respectively). Individual genes are indicated on the right.
PBS (CTR)
LPS 4h
VLP
LPS 8h
FLT3 – Fms-related tyrosine kinase 3
MRRF – Mitochondrial ribosome recycling factor
ITGAL – Integrin, alpha L
FLJ10597 – Chromosome 1 open reading frame 164
FLJ21919 – Chromosome 1 open reading frame 60
USP9Y – Ubiquitin specific protease 9
SF3B4 – Splicing factor 3b
MYOM2 – Myomesin 2
CPM - Carboxypeptidase M
PARP1 – Poly (ADP-ribosome) polymerase family
AZH1 – Enahncer of zeste homolog 1
cDNA FLJ46728
Growth arrest-specific 5
NAPSA – Napsin A aspartic peptidase
SNRP70 – Small nuclear ribonucleoprotein 70kD
CPS1 – Carbamoyl-phosphatase synthetase 1
PHLDA3 – Pleckstrin homology-like domain
CYFIP2 – p53 inducible protein
FLJ10916 – Hypothetical protein FLJ10916
RPL10 – ribosomal protein L10
LR8 – LR8 protein
Full-length insert cDNA clone ZD63C05
MAPK13 – mitogen-activated protein kinase 3
NFATC3 – Muclear factor of activated T-cells
FAM26B – Family with sequence similarity 26
FLJ35348 – FLJ35348
CTDSP2 – carboxy-terminal domain, RNA Pol II small protein
MOBKL2B – Mps One Binder kinase activator-like 2B
TNRC5 – Trinucleotide repeat containing 5
TARP – TCR gamma alternatereading frame protein
NFATC3 – Nuclear factor of activated T-cells
GRFL1 – Glucocorticoid receptor DNA binding factor 1
AKAP9 – A kinase anchor protein 9
RERE – Ariginine-glutamic acid dipeptide repeats
HIST1H2AC – Histone 1, H2ac
SLC10A3 – SOlute carrier family 10
RNF44 – Ring finger protein 44
S L C 5 A 1 2–S o l u t ec a r r i ef a m i l y5
NFATC3 – Nuclear factor of activated T cells
DHRS9 – Dehydrogenase/reductase member 9
CEBPA – CCAAT/enhancer binding protein
CEBPA – CCAAT/enhancer binding protein
ASPH Aspartate bea-hydroxylase
MCM7 – minichromosome mainteinance deficient 7
LOC339287 – Hypothetical protein LOC339287
CRTAP – Cartilage associated protein
PPP1R12B – protein phosphatase 1, regulatory subunit 12B
CD97 – CD97 antigen
CLCN7 – Chloride channel 7
PIK4CA – Phosphotidylinositol 4-kinaseJournal of Translational Medicine 2005, 3:45 http://www.translational-medicine.com/content/3/1/45
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induced modulation of transcriptional activity is effective
after as early as 4 hours and is persistent for the length of
the observation. Furthermore, the observed different
donor susceptibility to HIV-VLP-treatment may suggest
the possibility to select specific gene patterns useful for the
identification of "responsive" vaccinees. This would be
extremely helpful in understanding the eventual failure in
individuals enrolled in the clinical trials.
Among the pathways and specific genes activated in
MDDCs treated with HIV-VLPs, those directly involved in
the biological functions as antigen presenting cells (APCs)
have been analyzed in detail. The full functional matura-
tion and activation of MDDCs by HIV-VLPs has been con-
firmed and, in particular, the activation of genes involved
in cellular control (proliferation, differentiation, migra-
tion and homeostasis) as well as in functional activity
(antigen presentation, T cell activation and Th polariza-
tion) has been observed.
The ability of the HIV-VLP, as exogenous antigen, to
induce a CD8+ cytotoxic T lymphocyte (CTL) response, as
previously demonstrated in vivo, is supported by the acti-
vation of genes (such as beta 2 microglobulin) involved in
the antigen presentation within the context of major his-
tocompatibility complex (MHC) class I molecules as well
as in the Th1 polarization (IFN gamma and IL-18).
The presentation of an exogenous antigen in the context
of major histocompatibility complex (MHC) class I mole-
cules, to induce a CD8+ cytotoxic T lymphocyte (CTL)
response, is referred to as "cross-presentation", in alterna-
tive to the "direct" or "classic" presentation route for
endogenously synthesized proteins. The cross-presenta-
tion is a strategy employed only by DCs, among all the
antigen presenting cells, to ensure an anti-virus CTL
response also for those viruses which do not infect DCs
[47]. The CD8+ DC subset seems to be primarily involved
in this strategy [48,49], but the molecular mechanisms
underlying the cross-presentation are not yet fully eluci-
dated [50-52].
Microarray approach allows quantitative and simultane-
ous analysis of gene expression of a large amount of genes
and the systematic studies of expression patterns are
extremely useful for identify molecular events and key
pathways involved in cellular functions induced by spe-
cific stimuli. In this study, informative data on the global
pattern of gene expression underlying the activation of
MDDCs by HIV-VLPs at the early stages of the immune
response have been obtained. They may be extremely
helpful for the identification of exclusive activation mark-
ers to trace the biological effects of modifications/optimi-
zations of the HIV-VLP vaccination strategy.
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